Literature DB >> 25639867

Radiation promotes invasiveness of non-small-cell lung cancer cells through granulocyte-colony-stimulating factor.

Y-H Cui1, Y Suh1, H-J Lee2, K-C Yoo1, N Uddin1, Y-J Jeong2, J-S Lee3, S-G Hwang4, S-Y Nam5, M-J Kim6, S-J Lee1.   

Abstract

Despite ionizing radiation (IR) is being widely used as a standard treatment for lung cancer, many evidences suggest that IR paradoxically promotes cancer malignancy. However, its molecular mechanisms underlying radiation-induced cancer progression remain obscure. Here, we report that exposure to fractionated radiation (2 Gy per day for 3 days) induces the secretion of granulocyte-colony-stimulating factor (G-CSF) that has been commonly used in cancer therapies to ameliorate neutropenia. Intriguingly, radiation-induced G-CSF promoted the migratory and invasive properties by triggering the epithelial-mesenchymal cell transition (EMT) in non-small-cell lung cancer cells (NSCLCs). By irradiation, G-CSF was upregulated transcriptionally by β-catenin/TCF4 complex that binds to the promoter region of G-CSF as a transcription factor. Importantly, irradiation increased the stability of β-catenin through the activation of PI3K/AKT (phosphatidylinositol 3-kinase/AKT), thereby upregulating the expression of G-CSF. Radiation-induced G-CSF is recognized by G-CSFR and transduced its intracellular signaling JAK/STAT3 (Janus kinase/signal transducers and activators of transcription), thereby triggering EMT program in NSCLCs. Taken together, our findings suggest that the application of G-CSF in cancer therapies to ameliorate neutropenia should be reconsidered owing to its effect on cancer progression, and G-CSF could be a novel therapeutic target to mitigate the harmful effect of radiotherapy for the treatment of NSCLC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25639867     DOI: 10.1038/onc.2014.466

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  42 in total

Review 1.  Granulocyte colony-stimulating factor and its receptor.

Authors:  G D Demetri; J D Griffin
Journal:  Blood       Date:  1991-12-01       Impact factor: 22.113

2.  Effects of GM-CSF and M-CSF on tumor progression of lung cancer: roles of MEK1/ERK and AKT/PKB pathways.

Authors:  Yoshiki Uemura; Makoto Kobayashi; Hideshi Nakata; Tetsuya Kubota; Kentaro Bandobashi; Tsuyako Saito; Hirokuni Taguchi
Journal:  Int J Mol Med       Date:  2006-08       Impact factor: 4.101

Review 3.  Review: granulocyte colony-stimulating factor--role and relationships in infectious diseases.

Authors:  D C Dale; W C Liles; W R Summer; S Nelson
Journal:  J Infect Dis       Date:  1995-10       Impact factor: 5.226

4.  β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness.

Authors:  Ester Sánchez-Tilló; Oriol de Barrios; Laura Siles; Miriam Cuatrecasas; Antoni Castells; Antonio Postigo
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-11       Impact factor: 11.205

5.  Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity.

Authors:  Dexing Fang; David Hawke; Yanhua Zheng; Yan Xia; Jill Meisenhelder; Heinz Nika; Gordon B Mills; Ryuji Kobayashi; Tony Hunter; Zhimin Lu
Journal:  J Biol Chem       Date:  2007-02-07       Impact factor: 5.157

6.  Activation of the protein kinase a signal transduction pathway by granulocyte-macrophage colony-stimulating factor or by genetic manipulation reduces cytoskeletal organization in Lewis lung carcinoma variants.

Authors:  M R Young; S Charboneau; Y Lozano; A Djordjevic; M E Young
Journal:  Int J Cancer       Date:  1994-02-01       Impact factor: 7.396

7.  The role of granulocyte-colony stimulating factor (G-CSF) in the healthy brain: a characterization of G-CSF-deficient mice.

Authors:  Kai Diederich; Sevgi Sevimli; Henrike Dörr; Evelin Kösters; Maike Hoppen; Lars Lewejohann; Rainer Klocke; Jens Minnerup; Stefan Knecht; Sigrid Nikol; Norbert Sachser; Armin Schneider; Ali Gorji; Clemens Sommer; Wolf-Rüdiger Schäbitz
Journal:  J Neurosci       Date:  2009-09-16       Impact factor: 6.167

8.  A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis.

Authors:  Shicheng Su; Qiang Liu; Jingqi Chen; Jianing Chen; Fei Chen; Chonghua He; Di Huang; Wei Wu; Ling Lin; Wei Huang; Jin Zhang; Xiuying Cui; Fang Zheng; Haiyan Li; Herui Yao; Fengxi Su; Erwei Song
Journal:  Cancer Cell       Date:  2014-05-12       Impact factor: 31.743

9.  Effect of serum deprivation on constitutive production of granulocyte-colony stimulating factor and granulocyte macrophage-colony stimulating factor in lung cancer cells.

Authors:  Yoshiki Uemura; Makoto Kobayashi; Hideshi Nakata; Ryoji Harada; Tetsuya Kubota; Hirokuni Taguchi
Journal:  Int J Cancer       Date:  2004-05-10       Impact factor: 7.396

10.  AKT activation by N-cadherin regulates beta-catenin signaling and neuronal differentiation during cortical development.

Authors:  Jianing Zhang; Julie R Shemezis; Erin R McQuinn; Jing Wang; Maria Sverdlov; Anjen Chenn
Journal:  Neural Dev       Date:  2013-04-25       Impact factor: 3.842

View more
  22 in total

1.  Ablative versus fractionated radiation therapy: a controversial role in cancer invasion and metastasis.

Authors:  A Oweida; B Abdulkarim
Journal:  Oncogene       Date:  2016-04-25       Impact factor: 9.867

2.  Secretome of tumor-associated leukocytes augment epithelial-mesenchymal transition in positive lymph node breast cancer patients via activation of EGFR/Tyr845 and NF-κB/p65 signaling pathway.

Authors:  Eslam A Elghonaimy; Sherif A Ibrahim; Amal Youns; Zeinab Hussein; Mohamed Akram Nouh; Tahani El-Mamlouk; Mohamed El-Shinawi; Mona Mostafa Mohamed
Journal:  Tumour Biol       Date:  2016-06-22

Review 3.  Does the mobilization of circulating tumour cells during cancer therapy cause metastasis?

Authors:  Olga A Martin; Robin L Anderson; Kailash Narayan; Michael P MacManus
Journal:  Nat Rev Clin Oncol       Date:  2016-08-23       Impact factor: 66.675

4.  FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation.

Authors:  Yan-Hong Cui; Hyeonmi Kim; Minyoung Lee; Joo Mi Yi; Rae-Kwon Kim; Nizam Uddin; Ki-Chun Yoo; Jae Hyeok Kang; Mi-Young Choi; Hyuk-Jin Cha; Ok-Seon Kwon; In-Hwa Bae; Min-Jung Kim; Neha Kaushik; Su-Jae Lee
Journal:  Oncogene       Date:  2018-07-04       Impact factor: 9.867

5.  miR-1207-5p suppresses lung cancer growth and metastasis by targeting CSF1.

Authors:  Wei Dang; Zailong Qin; Songqing Fan; Qiuyuan Wen; Yuanjun Lu; Jia Wang; Xuemei Zhang; Lingyu Wei; Wei He; Qiurong Ye; Qun Yan; Guiyuan Li; Jian Ma
Journal:  Oncotarget       Date:  2016-05-31

Review 6.  Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation.

Authors:  Su Yeon Lee; Eui Kyong Jeong; Min Kyung Ju; Hyun Min Jeon; Min Young Kim; Cho Hee Kim; Hye Gyeong Park; Song Iy Han; Ho Sung Kang
Journal:  Mol Cancer       Date:  2017-01-30       Impact factor: 27.401

Review 7.  Roles of Long Noncoding RNAs in Recurrence and Metastasis of Radiotherapy-Resistant Cancer Stem Cells.

Authors:  Hsiang-Cheng Chi; Chung-Ying Tsai; Ming-Ming Tsai; Chau-Ting Yeh; Kwang-Huei Lin
Journal:  Int J Mol Sci       Date:  2017-09-05       Impact factor: 5.923

8.  MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy.

Authors:  Hideo Tomihara; Daisaku Yamada; Hidetoshi Eguchi; Yoshifumi Iwagami; Takehiro Noda; Tadafumi Asaoka; Hiroshi Wada; Koichi Kawamoto; Kunihito Gotoh; Yutaka Takeda; Masahiro Tanemura; Masaki Mori; Yuichiro Doki
Journal:  Cancer Sci       Date:  2017-03       Impact factor: 6.716

9.  Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling.

Authors:  Fanfan Zhu; Chunyan Dai; Yufei Fu; Jacky F C Loo; Dajin Xia; Sizhi P Gao; Zhongjun Ma; Zhe Chen
Journal:  Oncotarget       Date:  2016-02-23

10.  Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin.

Authors:  Joaquim Bosch-Barrera; Elia Sais; Noemí Cañete; Jordi Marruecos; Elisabet Cuyàs; Angel Izquierdo; Rut Porta; Manel Haro; Joan Brunet; Salvador Pedraza; Javier A Menendez
Journal:  Oncotarget       Date:  2016-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.